This page provides a comprehensive overview of clinical trials for [Alzheimer's disease](/diseases/alzheimers-disease) (AD), the most common neurodegenerative disorder affecting millions worldwide. The AD clinical trial landscape has undergone a transformative evolution in recent years, with the successful approval of disease-modifying therapies representing a paradigm shift in the field. This comprehensive resource covers the complete drug development pipeline from Phase 1 through Phase 3, highlighting recent regulatory approvals, ongoing trials, and emerging therapeutic targets.
Clinical trials are essential for developing new treatments and understanding disease mechanisms. The Alzheimer's disease drug development pipeline has expanded significantly, with over 140 agents currently in various stages of clinical investigation as of 2024[@cummings2024]. The field has learned critical lessons from both successful and failed trials, leading to improved trial designs, better patient selection using biomarker confirmation, and more meaningful clinical outcome measures.
This page provides a comprehensive overview of clinical trials for [Alzheimer's disease](/diseases/alzheimers-disease) (AD), the most common neurodegenerative disorder affecting millions worldwide. The AD clinical trial landscape has undergone a transformative evolution in recent years, with the successful approval of disease-modifying therapies representing a paradigm shift in the field. This comprehensive resource covers the complete drug development pipeline from Phase 1 through Phase 3, highlighting recent regulatory approvals, ongoing trials, and emerging therapeutic targets.
Clinical trials are essential for developing new treatments and understanding disease mechanisms. The Alzheimer's disease drug development pipeline has expanded significantly, with over 140 agents currently in various stages of clinical investigation as of 2024[@cummings2024]. The field has learned critical lessons from both successful and failed trials, leading to improved trial designs, better patient selection using biomarker confirmation, and more meaningful clinical outcome measures.
The modern era of AD clinical trials began in the 1980s with the first symptomatic treatments targeting the cholinergic system. Tacrine, the first approved AD medication, was followed by donepezil, rivastigmine, and galantamine—all cholinesterase inhibitors that provided modest symptomatic benefit but did not modify disease progression. These early trials established many of the methodological principles still used today, including the importance of standardized cognitive outcome measures and the need for placebo-controlled designs.
The failure of numerous disease-modifying therapies in the 2000s and early 2010s taught the field critical lessons about trial design. Many early anti-amyloid approaches failed because they targeted downstream pathology in patients with advanced disease, used inadequate outcome measures, or lacked biomarker confirmation of target engagement. The phase 3 trials of solanezumab, gantenerumab, and crenezumab all failed to meet their primary endpoints in earlier iterations, though subsequent analyses suggested potential benefits in specific patient subgroups[@aisen2020].
The period from 2019 to 2024 represents a watershed moment in AD clinical development. In 2021, aducanumab received accelerated approval from the FDA based on amyloid plaque reduction, despite controversy regarding clinical efficacy[@sevigny2016]. Although aducanumab was later withdrawn from the market, it paved the way for subsequent approvals. In 2023, lecanemab received full FDA approval following the CLARITY-AD trial demonstrating 27% slowing of cognitive decline[@van2023], and in 2024, donanemab received approval based on the TRAILBLAZER-ALZ 2 results showing 35% slowing in patients with low/medium tau pathology[@sims2023]. These approvals represent the first disease-modifying therapies to demonstrate clinically meaningful benefits in AD.
The approval of three anti-amyloid monoclonal antibodies represents the most significant advance in AD therapeutics. These therapies target different Aβ species and have demonstrated varying efficacy and safety profiles.
| Drug | Company | Mechanism | Phase | Status | NCT Number |
|------|---------|-----------|-------|--------|------------|
| [Lecanemab](/entities/lecanemab) (Leqembi) | [Biogen](/companies/biogen)/[Eisai](/companies/eisai) | Anti-[Aβ](/proteins/amyloid-beta) Protofibril | Phase 3 | Approved | NCT01767311 |
| [Donanemab](/entities/donanemab) (Kisunla) | Eli Lilly | Anti-Aβ Plaque | Phase 3 | Approved | NCT03367403 |
| Donanemab | Eli Lilly | Anti-Aβ Plaque | Phase 3 | Recruiting | NCT05538487 |
| Crenezumab | [Genentech](/companies/genentech)/[Roche](/companies/roche) | Anti-Aβ | Phase 3 | Completed | NCT01998841 |
| Gantenerumab | [Roche](/companies/roche) | Anti-Aβ | Phase 3 | Completed | NCT02051647 |
| Solanezumab | Eli Lilly | Anti-Aβ Monomer | Phase 3 | Completed | NCT02008357 |
The CLARITY-AD trial (NCT03887455) was a pivotal 18-month, randomized, double-blind, placebo-controlled Phase 3 study that enrolled 1,795 participants with early Alzheimer's disease (MCI due to AD or mild AD dementia) with confirmed amyloid pathology[@van2023]. The trial met its primary endpoint, demonstrating a 27% slowing of cognitive decline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) compared to placebo.
Primary Endpoint Results:
The TRAILBLAZER-ALZ 2 trial (NCT03367403) enrolled 1,736 participants with early symptomatic AD and demonstrated a 35% slowing of cognitive decline in patients with low/medium tau pathology[@sims2023]. Notably, donanemab achieved this benefit with a finite treatment course—participants could stop treatment once they reached amyloid clearance thresholds.
Key Findings:
Amyloid-related imaging abnormalities represent the primary safety consideration for all anti-amyloid therapies. ARIA comprises two main phenotypes: ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition)[@selleck2024].
| Drug | ARIA-E Rate (treatment) | ARIA-E Rate (placebo) | ARIA-H Rate (treatment) |
|------|------------------------|---------------------|------------------------|
| Lecanemab | 21% | 9% | 17% |
| Donanemab | 24% | 2% | 31% |
| Aducanumab | 35% | 3% | 19% |
Risk factors for ARIA include APOE ε4 carrier status, especially homozygosity, and concurrent anticoagulant use[@wang2024]. Most ARIA cases are mild to moderate, detected via MRI monitoring, and resolve with temporary treatment discontinuation. Strict MRI monitoring protocols are essential for patient safety.
Tau-targeted therapies represent the next frontier in AD drug development. While anti-amyloid therapies remove the upstream trigger, tau-targeted approaches aim to address downstream neurodegeneration.
| Drug | Company | Mechanism | Phase | Status | NCT Number |
|------|---------|-----------|-------|--------|------------|
| Semorinemab | [Genentech](/companies/genentech)/[Roche](/companies/roche) | Anti-[Tau](/proteins/tau) Antibody | Phase 2 | Completed | NCT03289143 |
| Gosuranemab | [Biogen](/companies/biogen) | Anti-Tau Antibody | Phase 2 | Completed | NCT03352557 |
| Tilavonemab | AbbVie | Anti-Tau Antibody | Phase 2 | Completed | NCT02880960 |
| E2814 | Eisai | Anti-Tau Antibody | Phase 1/2 | Recruiting | NCT05253061 |
Tau immunotherapy trials have yielded mixed results. While semorinemab failed to meet primary endpoints in the Tauria trial, post-hoc analyses suggested potential benefits in slower progressors. The field is now focusing on combination approaches targeting both amyloid and tau simultaneously[@depp2024].
Phase 2 trials represent a critical stage for validating novel mechanisms and identifying optimal dosing before large Phase 3 investments.
| Drug | Company | Mechanism | Phase | Status |
|------|---------|-----------|-------|--------|
| AL002 | Alector | [TREM2](/proteins/trem2) Agonist | Phase 2 | Recruiting |
| AL003 | Alector | SIGLEC-3 Antibody | Phase 1 | Recruiting |
| AC-002 | AC Immune | Tau Vaccine | Phase 2 | Recruiting |
| JBI-802 | Lioncrest | TREM2/CD33 Dual | Phase 1/2 | Recruiting |
Variants in the TREM2 gene are significant risk factors for late-onset AD, with the R47H variant conferring approximately 3-fold increased risk. TREM2 is expressed on microglia and plays a critical role in amyloid clearance and neuroinflammation[@bucci2023].
AL002 is a monoclonal antibody that activates TREM2, potentially enhancing microglial function. The Phase 2 INVOKE-2 trial (NCT05112882) is evaluating AL002 in early AD patients. This represents a novel mechanism targeting the innate immune system rather than amyloid or tau directly.
Neuroinflammation has emerged as a key therapeutic target, with several agents in development targeting different aspects of the inflammatory response.
| Drug | Company | Mechanism | Phase | Status |
|------|---------|-----------|-------|--------|
| INmune Bio XPro | INmune Bio | TNF-α Inhibitor | Phase 2 | Recruiting |
| Sargramostim | University of Colorado | GM-CSF | Phase 2 | Completed |
| Blarcamesine | Anavex | Sigma-1 Agonist | Phase 2/3 | Completed |
XPro (INm-007) is a selective TNF-α inhibitor designed to reduce neuroinflammation without causing broad immunosuppression. The Phase 2 trial (NCT05318989) is evaluating safety and efficacy in patients with mild cognitive impairment due to AD.
Phase 1 trials evaluate safety, tolerability, and pharmacokinetics in small numbers of participants, often including both healthy volunteers and patients.
| Drug | Company | Mechanism | Phase |
|------|---------|-----------|-------|
| ACI-35.170 | AC Immune | Tau Liposome Vaccine | Phase 1 |
| UB-313 | Vaxxinity | Aβ Vaccine | Phase 1 |
| AL042 | Alector | TREM2 Agonist | Phase 1 |
| JAB-230 | Janssen | Synaptic Marker Modulator | Phase 1 |
Vaccine strategies aim to induce endogenous antibody production against pathologic proteins. ACI-35.170 is a liposome-based vaccine targeting phosphorylated tau, designed to generate antibodies that recognize pathologically modified tau while avoiding off-target effects[@klunk2022].
Contemporary AD trials increasingly require biomarker confirmation of both diagnosis and target pathology, moving beyond purely clinical criteria[@jack2023].
Required Biomarkers:
Blood-based biomarkers are revolutionizing trial design by enabling less invasive screening and monitoring[@carroll2024].
| Biomarker | Utility | Status |
|-----------|---------|--------|
| p-tau181/p-tau217 | Amyloid/tau status | Validated |
| Neurofilament light chain (NfL) | Neurodegeneration | Validated |
| GFAP | Astrocyte activation | Emerging |
The NfL trajectory has been validated as an outcome measure in trials, with treatment effects on NfL change correlating with clinical outcomes[@garrigan2024].
Primary Clinical Outcomes:
Successful recent trials have employed several enrichment strategies to improve signal detection:
Understanding treatment response heterogeneity is critical for precision medicine approaches[@schneider2024]. Key subgroups include:
Many modern trials employ adaptive designs allowing modifications based on interim analyses:
The CLARITY-AD trial demonstrated significant slowing of cognitive decline in early AD patients with 27% reduction in CDR-SB score at 18 months[@van2023]. Key highlights included:
The TRAILBLAZER-ALZ 2 trial showed 35% slowing of cognitive decline in patients with low/medium tau pathology[@honig2024]. The finite treatment duration (stopping at amyloid clearance) offers a novel paradigm:
The field is moving toward combination therapies that address multiple pathological targets simultaneously[@chen2024]:
Prevention trials in preclinical AD represent the ultimate frontier:
Post-approval studies are generating real-world evidence:
Detailed pages for specific clinical trials:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate